HBIO Harvard Bioscience, Inc. - Common Stock
$7.06
价格 · 八月 19, 2026
截至...的财报数据 八月 11, 2026
52周区间
$0–$8
94% of range
分析师评级
BUY
8 analysts
目标价
$8
+6% upside
P/E (TTM)
-0.6
ROE
-384.8%
净利润率
-65.5%
关于 Harvard Bioscience, Inc. - Common Stock 公司概况（来自维基百科）
Harvard Bioscience is a global developer, manufacturer and marketer of life sciences equipment to support research and drug discovery. It is traded on NASDAQ under the stock symbol HBIO.
阅读更多
Harvard Bioscience is a global developer, manufacturer and marketer of life sciences equipment to support research and drug discovery. It is traded on NASDAQ under the stock symbol HBIO.
Headquartered in Holliston, Massachusetts, United States, the company's brands include: Biochrom, BTX, CMA, Data Sciences International (DSI), Harvard Apparatus, HEKA, Hugo Sachs Elektronik, KD Scientific, Multi Channel Systems (MCS), Panlab, and Warner Instruments. The company has approximately 355 employees, with 216 of those in the USA, and its principal manufacturing facilities are in New Brighton, Minnesota, Holliston, Massachusetts, Reutlingen, Germany, Barcelona, Spain, and March, Germany.
History
Harvard Bioscience was founded in 1901 by Dr. William T. Porter of Harvard Medical School. He began manufacturing his own physiology teaching equipment in the basement of the Harvard Medical School. Dr. Porter went on to found the American Journal of Physiology and became one of the leading physiologists of his day.
The company invented the mechanical syringe pump in the 1950s and a computer-controlled dosing pump in the 1980s.
In the early 1980s, the company started using the name Harvard Bioscience; the name was not officially changed to Harvard Bioscience, Inc. until 2000. The company completed their initial public offering on December 7, 2000. The names Harvard Apparatus and Harvard Bioscience are used pursuant to a license agreement between Harvard University and Harvard Bioscience, Inc.
From 1996 to 2005 the company completed 17 business acquisitions, including the BTX division acquisition in 2003.
In 2007 the company sold most of its Capital Equipment Business, including its Genomic Solutions division and its Belgian subsidiary, Maia Scientific.
The company spun off Harvard Apparatus Regenerative Technology, Inc. (HART) in 2013 and Jeff Duchemin became CEO in August 2013.
In 2014 the company acquired Multi Channel Systems MCS GmbH (MCS) and Triangle BioSystems, Inc. (TBSI).
In 2015 the company acquired HEKA Electronik of Germany.
In 2016 the company divested AHN Biotechnologie GmbH, which it acquired in 2012.
In 2018 Harvard Bioscience acquired St. Paul, Minnesota-based Data Sciences International for $71 million and sold its Denville Scientific subsidiary to Thomas Scientific for $20 million.
James Green was named President and CEO in July 2019 and the company's performance declined during the latter half of his six-year tenure. In 2019, the company's gross revenue was $116 million, down from $120.7 million in 2018. The company ended the year with $55 million in loans, down from $62.4 million in loans at the end of 2018. Loans were through Cerberus Capital and were subsequently refinanced in 2020 with a syndicate led by Citizens Financial Group. In September 2019 the company announced a restructuring program, including closing their Connecticut operation, downsizing in the United Kingdom, and a reduction in force of over 10% of headcount. Several additional restructurings were implemented from 2020 to 2024.
For approximately nine months in 2019-2020 the company had an activist investor in its stock, Engine Capital.
In 2020, during the COVID-19 pandemic, Harvard Bioscience received $6.1 million in federally backed small business loans from PNC Bank as part of the Paycheck Protection Program. The company promptly repaid this loan after receiving scrutiny related to it.
In the of summer of 2025 the board of directors of Harvard Bioscience was reconstituted and a new CEO was appointed and in December 2025 the company successfully refinanced its debt, obtaining a $40 million credit facility with BroadOak Capital.
Products
Harvard Bioscience offers a wide array of products for life science research. Their product portfolio is broken into five market segments: Fluidics, Laboratory Equipment & Supplies, Molecular Analysis, Cell Analysis, and Physiology.
Finance
The revenue of the company grew from $11.5 million in 1997 to $108.2 million in 2010, a CAGR of 19%. The revenue of the company for fy 2013 reached 105.57 million with the profit margin of 0.12% and operation margin of -1.01%.
In the 25 years since Harvard Bioscience went public in 2000, there have been several intervals in which the company's value was grossly misunderstood by the market and its stock significantly undervalued, including, most recently, in 2019 and 2026.
来源：维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗
HBIO 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$7.05
市值
$32M
P/E (TTM)
-0.6
每股收益 (TTM)
$-1.28
营收 (TTM)
$87M
股息收益率
—
ROE
-384.8%
负债/权益
2.6
52周区间
$0 – $8
HBIO 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
Configure
10年表现 收入、净利润、利润率和每股收益趋势
营收与净利润
$87M
2016-12-31
→
2025-12-31
EPS
$-1.28
2016-12-31
→
2025-12-31
自由现金流
$5M
2018-12-31
→
2025-12-31
利润率
-65.5%
2016-12-31
→
2025-12-31
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
指标
5年趋势
HBIO
同行中位数
P/E (TTM)
-0.6
31.3
P/S (TTM) (市销率 (TTM))
0.4
0.5
P/B (市净率)
2.3
1.3
EV / EBITDA (企业价值 / EBITDA)
-1.2
—
Price / FCF (股价/自由现金流)
5.8
—
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
指标
5年趋势
HBIO
同行中位数
Gross Margin (毛利率)
57.7%
47.0%
Operating Margin (营业利润率)
-56.1%
—
Net Profit Margin (净利润率)
-65.5%
-11.4%
ROA
-54.9%
-27.7%
ROE
-384.8%
-58.6%
ROIC
-96.8%
—
财务健康 债务、流动性、偿付能力 — 资产负债表强度
指标
5年趋势
HBIO
同行中位数
Debt / Equity (负债/股东权益比率)
2.6
—
Current Ratio (流动比率)
2.2
1.7
Quick Ratio (速动比率)
1.1
—
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
指标
5年趋势
HBIO
同行中位数
Revenue YoY (营收同比增长)
-8.1%
—
Revenue CAGR 3Y (营收3年复合年增长率)
-8.6%
—
Revenue CAGR 5Y (营收5年复合年增长率)
-3.2%
—
资本效率 资产周转率、库存周转率、应收账款周转率
指标
5年趋势
HBIO
同行中位数
HBIO 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
买入
8 位分析师
- 强烈买入 2 25.0%
- 买入 4 50.0%
- 持有 2 25.0%
- 卖出 0 0.0%
- 强烈卖出 0 0.0%
12个月价格目标
1 位分析师 · 2026-08-16
最低
$7.50
最高
$7.50
中位数目标
$7.50
+6.3%
平均目标
$7.50
+6.3%
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
0.05%
| 期间 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|
| 2026年6月30日 | $-0.14 | $-0.21 | 0.07% |
| 2026年3月31日 | $-0.33 | $-0.63 | 0.30% |
| 2025年12月31日 | $0.00 | $0.36 | -0.36% |
| 2025年9月30日 | $0.00 | $0.05 | -0.05% |
| 2025年6月30日 | $-0.10 | $-0.10 | 0.00% |
| 2025年3月31日 | $-0.10 | $-0.41 | 0.31% |
同行比较（GICS 子行业） 关键指标与行业同行对比
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| HBIO | $30M | -0.5 | -8.1% | -65.5% | -384.8% | 57.7% |
| HYFT | — | — | — | — | — | — |
| BNGO | $16M | -0.3 | -7.4% | -92.6% | -58.8% | — |
| CDT | — | — | — | — | — | — |
| TMO | $257.86B | 32.7 | 3.9% | 15.0% | 13.0% | — |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表 17
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $87M | $94M | $112M | $113M | $119M | $102M | $116M | $121M | $77M | $105M | $109M | $109M | |
| Cost of Revenue | $37M | $39M | $46M | $53M | $51M | $44M | $52M | $58M | $38M | $56M | $60M | $59M | |
| Gross Profit | $50M | $55M | $66M | $61M | $68M | $58M | $64M | $63M | $39M | $48M | $49M | $49M | |
| R&D Expense | $9M | $10M | $12M | $12M | $11M | $9M | $11M | $11M | $6M | $5M | $6M | $5M | |
| SG&A Expense | $18M | $21M | $23M | $24M | $24M | $24M | $23M | $21M | $18M | $21M | $20M | $17M | |
| Operating Expenses | $98M | $61M | $64M | $68M | $66M | $58M | $64M | $62M | $40M | $51M | $50M | $43M | |
| Operating Income | $-49M | $-6M | $2M | $-7M | $2M | $221.0K | $377.0K | $984.0K | $-635.0K | $-3M | $-2M | $7M | |
| Interest Expense | · | · | · | · | · | · | · | $5M | $713.0K | $639.0K | $846.0K | $990.0K | |
| Other Non-op | $-3M | $-325.0K | $-227.0K | $302.0K | $-666.0K | $-806.0K | $-469.0K | $-4M | $-739.0K | $-179.0K | $-1M | $-1M | |
| Pretax Income | $-57M | $-12M | $-3M | $-9M | $-140.0K | $-7M | $-6M | $-8M | $-3M | $-3M | $-4M | $4M | |
| Income Tax | $-686.0K | $740.0K | $859.0K | $337.0K | $148.0K | $518.0K | $-815.0K | $-4M | $-605.0K | $1M | $15M | $2M | |
| Net Income | $-57M | $-12M | $-3M | $-10M | $-288.0K | $-8M | $-5M | $-3M | $-865.0K | $-4M | $-19M | $2M | |
| EPS (Basic) | $-1.28 | $-0.28 | $-0.08 | $-0.23 | $-0.01 | · | $-0.12 | $-0.08 | $-0.02 | $-0.13 | $-0.57 | $0.07 | |
| EPS (Diluted) | $-1.28 | $-0.28 | $-0.08 | $-0.23 | · | · | $-0.12 | $-0.08 | $-0.02 | $-0.13 | $-0.57 | $0.07 | |
| Shares (Basic) | 44,391,000 | 43,538,000 | 42,420,000 | 41,413,000 | 40,343,000 | 38,640,000 | 37,813,580 | 36,453,126 | 34,753,325 | 34,211,521 | 33,592,775 | 32,170,683 | |
| Shares (Diluted) | 44,391,000 | 43,538,000 | 42,420,000 | 41,413,000 | 40,343,000 | 38,640,000 | 37,813,580 | 36,453,126 | 34,753,325 | 34,211,521 | 33,592,775 | 33,236,569 | |
| EBITDA | $-49M | $-6M | $2M | $-7M | $2M | $221.0K | $377.0K | $984.0K | $-101.0K | $-3M | $-2M | · |
资产负债表 28
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9M | $4M | $4M | $5M | $8M | $8M | $8M | $8M | $6M | $6M | $7M | $14M | |
| Receivables | $16M | $15M | $16M | $17M | $22M | $18M | $21M | $21M | $13M | $16M | $18M | $16M | |
| Inventory | $21M | $23M | $25M | $26M | $28M | $22M | $22M | $25M | $17M | $20M | $22M | $21M | |
| Other Current Assets | $3M | $3M | $4M | $3M | $4M | $3M | $2M | $3M | $4M | $4M | $4M | $5M | |
| Current Assets | $48M | $45M | $49M | $51M | $62M | $52M | $54M | $58M | $48M | $45M | $51M | $57M | |
| PP&E (Net) | $5M | $5M | $4M | $3M | $3M | $4M | $5M | $6M | $4M | $4M | $6M | $5M | |
| PP&E (Gross) | $23M | $21M | $18M | $18M | $18M | $21M | $20M | $23M | $19M | $19M | $22M | $20M | |
| Accum. Depreciation | $18M | $16M | $14M | $15M | $14M | $17M | $15M | $17M | $16M | $15M | $16M | $15M | |
| Goodwill | $10M | $56M | $57M | $56M | $58M | $59M | $57M | $57M | $36M | $38M | $40M | $40M | |
| Intangibles | $8M | $11M | $16M | $21M | $27M | $33M | $38M | $46M | $10M | $17M | $21M | $21M | |
| Other Non-current Assets | $3M | $3M | $6M | $8M | $5M | $1M | $2M | $2M | $324.0K | $128.0K | $152.0K | $380.0K | |
| Total Assets | $80M | $127M | $137M | $145M | $162M | $156M | $165M | $169M | $109M | $108M | $120M | $136M | |
| Accounts Payable | $4M | $5M | $6M | $6M | $5M | $6M | $5M | $7M | $4M | $6M | $9M | $6M | |
| Accrued Liabilities | · | · | · | · | · | · | $6M | $7M | $4M | $5M | $4M | $4M | |
| Current Liabilities | $22M | $55M | $27M | $23M | $25M | $21M | $25M | $25M | $14M | $15M | $19M | $18M | |
| Capital Leases | $7M | $6M | $5M | $5M | $6M | $7M | $8M | · | · | · | · | · | |
| Deferred Tax | $317.0K | $710.0K | $776.0K | $590.0K | $2M | $2M | $2M | $2M | $3M | $6M | $4M | $1M | |
| Other Non-current Liabilities | $1M | $1M | $1M | $1M | $486.0K | $3M | $749.0K | $3M | · | · | · | · | |
| Total Liabilities | $66M | $63M | $64M | $73M | $79M | $80M | $83M | $86M | $28M | $36M | $42M | $40M | |
| Long-term Debt | $36M | $37M | $37M | $47M | $48M | $48M | $54M | $61M | $12M | $14M | $19M | $21M | |
| Total Debt | $36M | $37M | $37M | $47M | $49M | $48M | $50M | $59M | $9M | $11M | $16M | · | |
| Common Stock | $447.0K | $441.0K | $434.0K | $454.0K | $452.0K | $444.0K | $438.0K | $436.0K | $419.0K | $418.0K | $416.0K | $397.0K | |
| Retained Earnings | $-215M | $-158M | $-146M | $-142M | $-133M | $-132M | $-125M | $-120M | $-117M | $-116M | $-112M | $-93M | |
| Treasury Stock | · | · | · | · | $0 | $11M | · | · | · | · | · | · | |
| AOCI | $-12M | $-16M | $-14M | $-15M | $-10M | $-13M | $-13M | $-14M | $-11M | $-17M | $-12M | $-8M | |
| Stockholders' Equity | $14M | $63M | $73M | $72M | $83M | $77M | $82M | $83M | $81M | $72M | $78M | $95M | |
| Liabilities + Equity | $80M | $127M | $137M | $145M | $162M | $156M | $165M | $169M | $109M | $108M | $120M | $136M | |
| Shares Outstanding | 4,471,989 | 44,074,475 | 43,394,509 | 42,081,707 | 41,142,876 | 39,407,080 | 38,188,208 | 37,378,802 | 35,018,478 | 35,018,478 | 33,979,265 | 32,563,256 |
现金流 16
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $4M | $5M | $4M | $4M | $4M | $3M | $3M | $4M | $3M | $3M | $2M | |
| Deferred Tax | $-553.0K | $310.0K | $228.0K | $-498.0K | $-371.0K | $-143.0K | $-398.0K | $-4M | $-2M | $-279.0K | $15M | $1M | |
| Amort. of Intangibles | $4M | $5M | $6M | $6M | $6M | $6M | $6M | $5M | $2M | $3M | $3M | $3M | |
| Restructuring | $200.0K | $800.0K | $391.0K | $2M | $1M | $2M | $1M | · | $0 | $-4.0K | $788.0K | $1M | |
| Operating Cash Flow | $7M | $1M | $14M | $1M | $1M | $9M | $8M | $3M | $1M | $5M | $705.0K | $4M | |
| CapEx | $1M | $3M | $2M | $2M | $1M | $1M | $1M | $986.0K | $890.0K | · | · | · | |
| Investing Cash Flow | $-2M | $-1M | $-2M | $-2M | $-1M | $-1M | $-229.0K | $-54M | $-917.0K | $-62.0K | $-8M | $-14M | |
| Debt Issued | $40M | $0 | · | · | · | · | · | · | · | · | · | · | |
| Net Debt Issued | $15M | $-6M | $-4M | $-3M | $-4M | $-67M | $-12M | $-20M | $-5M | $-9M | $-8M | · | |
| Stock Issued | · | · | · | · | · | · | · | $5M | $160.0K | $182.0K | $2M | $2M | |
| Net Stock Activity | · | · | · | · | · | · | · | $5M | $160.0K | $182.0K | $2M | · | |
| Financing Cash Flow | $-1M | $-131.0K | $-12M | $-3M | $-252.0K | $-8M | $-8M | $53M | $-2M | $-5M | $-540.0K | $-1M | |
| Net Change in Cash | $5M | $-175.0K | $-225.0K | $-3M | $-496.0K | $-18.0K | $162.0K | $2M | $137.0K | $-1M | $-7M | $-12M | |
| Taxes Paid | $-98.0K | $-159.0K | $207.0K | $534.0K | $577.0K | $416.0K | $374.0K | $98.0K | $13.0K | · | · | · | |
| Free Cash Flow | $5M | $-1M | $12M | $-438.0K | $67.0K | $8M | $7M | $2M | · | · | · | · | |
| Levered FCF | · | · | · | · | · | · | · | $-995.1K | · | · | · | · |
盈利能力 8
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 57.7% | 58.2% | 58.9% | 53.7% | 56.9% | 56.9% | 55.4% | 52.3% | 46.7% | 46.3% | 44.8% | · | |
| Operating Margin | -56.1% | -6.6% | 1.7% | -6.1% | 1.7% | 0.22% | 0.32% | 0.81% | -0.10% | -2.9% | -1.6% | · | |
| Net Margin | -65.5% | -13.2% | -3.0% | -8.4% | -0.24% | -7.6% | -4.0% | -2.4% | -0.85% | -4.1% | -17.5% | · | |
| Pretax Margin | -66.3% | -12.4% | -2.3% | -8.1% | -0.12% | -7.1% | -4.7% | -6.6% | -2.1% | -2.9% | -3.3% | · | |
| EBITDA Margin | -56.1% | -6.6% | 1.7% | -6.1% | 1.7% | 0.22% | 0.32% | 0.81% | -0.10% | -2.9% | -1.6% | · | |
| ROA | -54.9% | -9.4% | -2.4% | -6.2% | -0.18% | -4.9% | -2.8% | -2.1% | -0.80% | -3.8% | -14.9% | · | |
| ROE | -384.8% | -19.3% | -4.6% | -13.2% | -0.36% | -10.2% | -5.9% | -3.6% | -1.1% | -5.8% | -22.0% | · | |
| ROIC | -96.8% | -6.6% | 2.3% | -6.0% | 3.2% | 0.19% | 0.24% | 0.37% | -0.05% | -5.0% | -9.6% | · |
流动性与偿付能力 5
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.2 | 0.8 | 1.8 | 2.2 | 2.4 | 2.5 | 2.1 | 2.7 | 3.4 | 3.1 | 2.6 | · | |
| Quick Ratio | 1.1 | 0.3 | 0.8 | 0.9 | 1.2 | 1.2 | 1.1 | 1.4 | 1.6 | 1.5 | 1.3 | · | |
| Debt / Equity | 2.6 | 0.6 | 0.5 | 0.7 | 0.6 | 0.6 | 0.6 | 0.7 | 0.1 | 0.2 | 0.2 | · | |
| LT Debt / Equity | 2.6 | 0.0 | 0.4 | 0.6 | 0.5 | 0.6 | 0.6 | 0.7 | 0.1 | 0.2 | 0.2 | · | |
| Interest Coverage | · | · | · | · | · | · | · | 0.2 | -0.1 | -4.7 | -2.0 | · |
效率 3
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.7 | 0.8 | 0.7 | 0.7 | 0.6 | 0.7 | 0.9 | 0.9 | 0.9 | 0.8 | · | |
| Inventory Turnover | 1.7 | 1.6 | 1.8 | 1.9 | 2.1 | 2.0 | 2.2 | 2.7 | 2.6 | 2.7 | 2.8 | · | |
| Receivables Turnover | 5.6 | 6.1 | 6.8 | 5.9 | 6.0 | 5.3 | 5.5 | 6.9 | 6.4 | 6.3 | 6.5 | · |
增长率 3
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -8.1% | -16.1% | -0.96% | -4.7% | 16.5% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -8.6% | -7.5% | 3.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -3.2% | · | · | · | · | · | · | · | · | · | · | · |
估值 (TTM) 13
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $87M | $94M | $112M | $113M | $119M | $102M | $116M | $121M | $77M | $105M | $109M | $109M | |
| Net Income TTM | $-57M | $-12M | $-3M | $-10M | $-288.0K | $-8M | $-5M | $-3M | $-865.0K | $-4M | $-19M | $2M | |
| Market Cap | $30M | $93M | $232M | $117M | $290M | $169M | $116M | $119M | $116M | $105M | $118M | · | |
| Enterprise Value | $57M | $126M | $265M | $159M | $331M | $209M | $158M | $169M | $119M | $111M | $128M | · | |
| P/E | -0.5 | -7.5 | -66.9 | -12.0 | · | -20.4 | -25.4 | -39.8 | -165.0 | -23.5 | -6.1 | 81.0 | |
| P/S | 0.3 | 1.0 | 2.1 | 1.0 | 2.4 | 1.7 | 1.0 | 1.0 | 1.5 | 1.0 | 1.1 | · | |
| P/B | 2.2 | 1.5 | 3.2 | 1.6 | 3.5 | 2.2 | 1.4 | 1.4 | 1.4 | 1.5 | 1.5 | · | |
| P / Cash Flow | 4.5 | 64.6 | 16.5 | 101.2 | 229.8 | 18.1 | 14.5 | 41.2 | 109.3 | 19.5 | 167.2 | · | |
| P / FCF | 5.5 | -77.2 | 19.0 | -266.1 | 4329.2 | 20.7 | 17.1 | 62.6 | · | · | · | · | |
| EV / EBITDA | -1.2 | -20.3 | 139.8 | -23.0 | 160.1 | 945.8 | 419.8 | 172.2 | -1176.3 | -37.0 | -74.5 | · | |
| EV / FCF | 10.5 | -104.8 | 21.6 | -363.4 | 4938.0 | 25.6 | 23.2 | 89.3 | · | · | · | · | |
| EV / Revenue | 0.7 | 1.3 | 2.4 | 1.4 | 2.8 | 2.0 | 1.4 | 1.4 | 1.5 | 1.1 | 1.2 | · | |
| Earnings Yield | -191.0% | -13.3% | -1.5% | -8.3% | · | -4.9% | -3.9% | -2.5% | -0.61% | -4.3% | -16.4% | 1.2% |
损益表 16
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $23M | $21M | $24M | $21M | $20M | $22M | $25M | $22M | $23M | $25M | $28M | $25M | $29M | $30M | $28M | $27M | |
| Cost of Revenue | $10M | $9M | $10M | $9M | $9M | $10M | $11M | $9M | $10M | $10M | $12M | $11M | $12M | $12M | $13M | $15M | |
| Gross Profit | $13M | $12M | $14M | $12M | $12M | $12M | $14M | $13M | $13M | $15M | $16M | $15M | $17M | $18M | $16M | $12M | |
| R&D Expense | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | |
| SG&A Expense | $5M | $5M | $4M | $4M | $4M | $5M | $5M | $5M | $6M | $6M | $5M | $6M | $5M | $6M | $6M | $6M | |
| Operating Expenses | $14M | $13M | $12M | $12M | $12M | $62M | $14M | $15M | $15M | $17M | $16M | $16M | $16M | $17M | $16M | $16M | |
| Operating Income | $-978.0K | $-1M | $2M | $197.0K | $-819.0K | $-50M | $11.0K | $-2M | $-2M | $-2M | $282.0K | $-933.0K | $796.0K | $2M | $-457.0K | $-4M | |
| Other Non-op | $-125.0K | $-405.0K | $-1M | $-365.0K | $-434.0K | $-193.0K | $516.0K | $-518.0K | $-181.0K | $-142.0K | $-332.0K | $45.0K | $-372.0K | $432.0K | $465.0K | $-179.0K | |
| Pretax Income | $-3M | $-3M | $-3M | $-1M | $-2M | $-51M | $590.0K | $-4M | $-3M | $-4M | $-1M | $-562.0K | $-2M | $1M | $-892.0K | $-5M | |
| Income Tax | $14.0K | $117.0K | $-357.0K | $97.0K | $28.0K | $-454.0K | $572.0K | $311.0K | $-353.0K | $210.0K | $715.0K | $677.0K | $-1M | $585.0K | $774.0K | $-1M | |
| Net Income | $-3M | $-3M | $-3M | $-1M | $-2M | $-50M | $18.0K | $-5M | $-3M | $-5M | $-2M | $-1M | $-980.0K | $622.0K | $-2M | $-3M | |
| EPS (Basic) | $-0.64 | $-0.77 | $-0.06 | $-0.03 | $-0.52 | $-11.42 | $0.01 | $-0.11 | $-0.07 | $-0.11 | $-0.04 | $-0.03 | $-0.02 | $0.01 | $-0.04 | $-0.08 | |
| EPS (Diluted) | $-0.64 | $-0.77 | $-0.06 | $-0.03 | $-0.52 | $-11.42 | $0.01 | $-0.11 | $-0.07 | $-0.11 | $-0.04 | $-0.03 | $-0.02 | $0.01 | $-0.04 | $-0.08 | |
| Shares (Basic) | 4,526,000 | 4,473,000 | -88,564,000 | 44,556,000 | 4,430,000 | 4,410,000 | -86,964,000 | 43,614,000 | 43,486,000 | 43,402,000 | -84,741,000 | 42,688,000 | 42,354,000 | 42,119,000 | -82,747,000 | 41,637,000 | |
| Shares (Diluted) | 4,526,000 | 4,473,000 | -88,564,000 | 44,556,000 | 4,430,000 | 4,410,000 | -86,964,000 | 43,614,000 | 43,486,000 | 43,402,000 | -85,405,000 | 42,688,000 | 42,354,000 | 42,783,000 | -84,003,000 | 41,637,000 | |
| EBITDA | $-978.0K | $-1M | · | $197.0K | $-819.0K | $-50M | · | $-2M | $-2M | $-2M | · | $-933.0K | $796.0K | $2M | · | $-4M |
资产负债表 26
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7M | $7M | $9M | $7M | $7M | $6M | $4M | $5M | $4M | $4M | $4M | $5M | $4M | $4M | $5M | $5M | |
| Receivables | $14M | $15M | $16M | $12M | $12M | $13M | $15M | $13M | $12M | $15M | $16M | $15M | $17M | $18M | $17M | $15M | |
| Inventory | $22M | $22M | $21M | $22M | $22M | $23M | $23M | $26M | $25M | $24M | $25M | $26M | $26M | $27M | $26M | $26M | |
| Other Current Assets | $3M | $4M | $3M | $3M | $3M | $3M | $3M | $3M | $5M | $4M | $4M | $4M | $5M | $4M | $3M | $6M | |
| Current Assets | $46M | $47M | $48M | $44M | $45M | $45M | $45M | $47M | $46M | $48M | $49M | $50M | $53M | $52M | $51M | $52M | |
| PP&E (Net) | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $4M | $4M | $3M | $3M | $3M | $3M | $4M | |
| PP&E (Gross) | · | · | $23M | · | · | · | $21M | · | · | · | $18M | · | · | · | $18M | · | |
| Accum. Depreciation | · | · | $18M | · | · | · | $16M | · | · | · | $14M | · | · | · | $15M | · | |
| Goodwill | $9M | $9M | $10M | $10M | $10M | $9M | $56M | $57M | $57M | $57M | $57M | $56M | $57M | $57M | $56M | $55M | |
| Intangibles | $6M | $7M | $8M | $8M | $9M | $10M | $11M | $12M | $13M | $15M | $16M | $17M | $18M | $20M | $21M | $22M | |
| Other Non-current Assets | $3M | $3M | $3M | $4M | $4M | $4M | $3M | $3M | $3M | $5M | $6M | $8M | $6M | $8M | $8M | $8M | |
| Total Assets | $76M | $78M | $80M | $78M | $80M | $80M | $127M | $131M | $129M | $133M | $137M | $140M | $143M | $146M | $145M | $147M | |
| Accounts Payable | $6M | $5M | $4M | $5M | $5M | $5M | $5M | $5M | $6M | $6M | $6M | $6M | $5M | $6M | $6M | $6M | |
| Current Liabilities | $25M | $24M | $22M | $54M | $55M | $56M | $55M | $23M | $23M | $26M | $27M | $24M | $23M | $23M | $23M | $21M | |
| Capital Leases | $6M | $6M | $7M | $7M | $7M | $7M | $6M | $7M | $5M | $5M | $5M | $4M | $5M | $5M | $5M | $6M | |
| Deferred Tax | $311.0K | $313.0K | $317.0K | $733.0K | $734.0K | $717.0K | $710.0K | $707.0K | $764.0K | $772.0K | $776.0K | $661.0K | $667.0K | $546.0K | $590.0K | $1M | |
| Other Non-current Liabilities | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $1M | $1M | $892.0K | $1M | $1M | $1M | $420.0K | |
| Total Liabilities | $69M | $68M | $66M | $64M | $64M | $65M | $63M | $66M | $62M | $64M | $64M | $65M | $68M | $71M | $73M | $75M | |
| Long-term Debt | $37M | $36M | $36M | $34M | $35M | $36M | $37M | $38M | $36M | $36M | $37M | $39M | $41M | $44M | $47M | $49M | |
| Total Debt | $37M | $36M | · | · | · | · | · | $38M | $36M | $36M | · | $39M | $42M | $44M | · | $50M | |
| Common Stock | $447.0K | $447.0K | $447.0K | $446.0K | $445.0K | $442.0K | $441.0K | $436.0K | $436.0K | $434.0K | $434.0K | $457.0K | $457.0K | $455.0K | $454.0K | $453.0K | |
| Retained Earnings | $-221M | $-218M | $-215M | $-212M | $-211M | $-208M | $-158M | $-158M | $-153M | $-150M | $-146M | $-144M | $-143M | $-142M | $-142M | $-141M | |
| AOCI | $-12M | $-12M | $-12M | $-12M | $-12M | $-14M | $-16M | $-13M | $-15M | $-15M | $-14M | $-15M | $-14M | $-15M | $-15M | $-16M | |
| Stockholders' Equity | $7M | $10M | $14M | $14M | $16M | $15M | $63M | $65M | $67M | $69M | $73M | $74M | $75M | $74M | $72M | $72M | |
| Liabilities + Equity | $76M | $78M | $80M | $78M | $80M | $80M | $127M | $131M | $129M | $133M | $137M | $140M | $143M | $146M | $145M | $147M | |
| Shares Outstanding | 4,552,305 | 4,510,182 | 44,719,894 | 44,579,665 | 44,531,198 | 44,213,746 | 44,074,475 | 43,616,621 | 43,610,883 | 43,421,251 | 43,394,509 | 42,688,246 | 42,688,246 | 42,190,043 | 42,081,707 | 41,657,688 |
现金流 11
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $380.0K | $257.0K | $459.0K | $324.0K | $472.0K | $600.0K | $961.0K | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | |
| Amort. of Intangibles | $820.0K | $820.0K | $850.0K | $855.0K | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | |
| Restructuring | $318.0K | $235.0K | $29.0K | $48.0K | $30.0K | $93.0K | $225.0K | $179.0K | $396.0K | $0 | · | · | · | · | $485.0K | $1M | |
| Operating Cash Flow | $325.0K | $-662.0K | $-96.0K | $1M | $3M | $3M | $2M | $-842.0K | $-846.0K | $1M | $4M | $4M | $4M | $2M | $3M | $649.0K | |
| CapEx | $688.0K | $426.0K | $449.0K | $207.0K | $89.0K | $513.0K | $301.0K | $880.0K | $818.0K | $645.0K | $830.0K | $217.0K | $517.0K | $224.0K | $235.0K | $442.0K | |
| Investing Cash Flow | $-916.0K | $-620.0K | $-599.0K | $-348.0K | $-233.0K | $-683.0K | $-466.0K | $-1M | $458.0K | $-225.0K | $-1M | $-401.0K | $-625.0K | $288.0K | $-235.0K | $-442.0K | |
| Net Debt Issued | · | $0 | · | · | · | $-1M | · | · | · | $-3M | · | · | · | $-2M | · | · | |
| Financing Cash Flow | $-38.0K | $-9.0K | $2M | $-1M | $-1M | $-1M | $-1M | $2M | $177.0K | $-1M | $-4M | $-3M | $-2M | $-3M | $-3M | $377.0K | |
| Net Change in Cash | $-595.0K | $-2M | $2M | $-625.0K | $2M | $1M | $-461.0K | $521.0K | $-207.0K | $-28.0K | $-1M | $1M | $535.0K | $-719.0K | $-636.0K | $885.0K | |
| Taxes Paid | $-164.0K | $-5.0K | $-144.0K | $-2.0K | $46.0K | $2.0K | $-474.0K | $184.0K | $105.0K | $26.0K | $39.0K | $53.0K | $249.0K | $-134.0K | $41.0K | $141.0K | |
| Free Cash Flow | · | $-1M | · | · | · | $2M | · | · | · | $758.0K | · | · | · | $2M | · | · |
盈利能力 8
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 55.6% | 59.0% | · | 58.4% | 56.4% | 56.0% | · | 58.1% | 57.2% | 60.3% | · | 58.1% | 58.0% | 61.2% | · | 45.2% | |
| Operating Margin | -4.3% | -5.7% | · | 0.96% | -4.0% | -228.1% | · | -8.5% | -9.0% | -9.3% | · | -3.7% | 2.8% | 5.8% | · | -14.0% | |
| Net Margin | -12.8% | -16.5% | · | -6.0% | -11.2% | -231.2% | · | -21.9% | -12.7% | -19.1% | · | -4.9% | -3.4% | 2.1% | · | -12.7% | |
| Pretax Margin | -12.7% | -15.9% | · | -5.5% | -11.0% | -233.3% | · | -20.4% | -14.2% | -18.3% | · | -2.2% | -7.3% | 4.0% | · | -17.4% | |
| EBITDA Margin | -4.3% | -5.7% | · | 0.96% | -4.0% | -228.1% | · | -8.5% | -9.0% | -9.3% | · | -3.7% | 2.8% | 5.8% | · | -14.0% | |
| ROA | -3.7% | -4.3% | · | -1.2% | -2.2% | -47.3% | · | -3.5% | -2.1% | -3.4% | · | -0.86% | -0.66% | 0.41% | · | -2.3% | |
| ROE | -25.1% | -27.5% | · | -3.1% | -5.5% | -120.4% | · | -6.9% | -4.1% | -6.6% | · | -1.7% | -1.3% | 0.83% | · | -4.6% | |
| ROIC | -2.2% | -2.6% | · | 1.5% | -5.3% | -331.8% | · | -1.9% | -1.8% | -2.3% | · | -1.8% | 0.32% | 0.76% | · | -2.2% |
流动性与偿付能力 4
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.9 | 2.0 | · | 0.8 | 0.8 | 0.8 | · | 2.1 | 2.1 | 1.9 | · | 2.1 | 2.3 | 2.3 | · | 2.4 | |
| Quick Ratio | 0.8 | 0.9 | · | 0.3 | 0.4 | 0.3 | · | 0.8 | 0.7 | 0.8 | · | 0.8 | 0.9 | 0.9 | · | 0.9 | |
| Debt / Equity | 4.9 | 3.6 | · | · | · | · | · | 0.6 | 0.5 | 0.5 | · | 0.5 | 0.6 | 0.6 | · | 0.7 | |
| LT Debt / Equity | 4.9 | 3.6 | · | · | · | · | · | 0.5 | 0.5 | 0.5 | · | 0.5 | 0.5 | 0.6 | · | 0.6 |
效率 3
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | 0.5 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.6 | |
| Receivables Turnover | 1.7 | 1.5 | · | 1.7 | 1.7 | 1.5 | · | 1.6 | 1.6 | 1.5 | · | 1.7 | 1.7 | 1.6 | · | 1.6 |
估值 (TTM) 14
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $85M | $84M | · | $85M | $87M | $91M | · | $95M | $102M | $109M | · | $111M | $115M | $115M | · | $115M | |
| Net Income TTM | $-10M | $-57M | · | $-59M | $-60M | $-63M | · | $-14M | $-10M | $-6M | · | $-5M | $-1M | $-7M | · | $-8M | |
| Market Cap | $28M | $22M | · | $20M | $20M | $25M | · | $117M | $124M | $184M | · | $184M | $234M | $177M | · | $107M | |
| Enterprise Value | $58M | $51M | · | · | · | · | · | $151M | $156M | $216M | · | $217M | $272M | $218M | · | $151M | |
| P/E | -3.1 | -0.4 | · | -0.3 | -0.3 | -0.4 | · | -8.4 | -12.4 | -28.3 | · | -35.8 | -183.0 | -23.3 | · | · | |
| P/S | 0.3 | 0.3 | · | 0.2 | 0.2 | 0.3 | · | 1.2 | 1.2 | 1.7 | · | 1.7 | 2.0 | 1.5 | · | 0.9 | |
| P/B | 3.8 | 2.2 | · | 1.4 | 1.2 | 1.7 | · | 1.8 | 1.8 | 2.7 | · | 2.5 | 3.1 | 2.4 | · | 1.5 | |
| P / Tangible Book | · | · | · | · | · | · | · | · | · | · | · | 189.4 | 897.9 | · | · | · | |
| P / Cash Flow | · | -33.2 | · | · | · | 8.4 | · | · | · | 131.2 | · | · | · | 97.8 | · | · | |
| P / FCF | · | -20.2 | · | · | · | 10.2 | · | · | · | 242.9 | · | · | · | 111.6 | · | · | |
| EV / EBITDA | -59.5 | -43.5 | · | · | · | · | · | -80.6 | -75.5 | -94.7 | · | -232.8 | 341.4 | 124.5 | · | -40.1 | |
| EV / FCF | · | -46.9 | · | · | · | · | · | · | · | 284.6 | · | · | · | 137.1 | · | · | |
| EV / Revenue | 0.7 | 0.6 | · | · | · | · | · | 1.6 | 1.5 | 2.0 | · | 2.0 | 2.4 | 1.9 | · | 1.3 | |
| Earnings Yield | -31.9% | -251.9% | · | -302.3% | -311.4% | -250.9% | · | -11.9% | -8.1% | -3.5% | · | -2.8% | -0.55% | -4.3% | · | · |
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
损益表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 收入 | $87M | $94M | $112M | $113M | $119M |
| 毛利率 % | 57.7% | 58.2% | 58.9% | 53.7% | 56.9% |
| 营业利润率 % | -56.1% | -6.6% | 1.7% | -6.1% | 1.7% |
| 净收入 | $-57M | $-12M | $-3M | $-10M | $-288.0K |
| 稀释后每股收益 (EPS) | $-1.28 | $-0.28 | $-0.08 | $-0.23 | — |
资产负债表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 负债/股东权益比率 | 2.6 | 0.6 | 0.5 | 0.7 | 0.6 |
| 流动比率 | 2.2 | 0.8 | 1.8 | 2.2 | 2.4 |
| 速动比率 | 1.1 | 0.3 | 0.8 | 0.9 | 1.2 |
现金流
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 自由现金流 | $5M | $-1M | $12M | $-438.0K | $67.0K |
我的指标 您的个人关注列表 — 来自完整基本面的选定行
📊
选择对您重要的指标 — 点击上方完整基本面中任意行的 ➕。
您的选择已保存，并会跟随您浏览所有股票。
机构持有人 (13F) 9 家申报者 · $5.5M 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 0 (0 与上一季度对比) | 0 (-57 与上一季度对比) | 2 (+2 与上一季度对比) | 0 (-3 与上一季度对比) | +90K |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| AMH Equity Ltd | $1774844 | 4047535 | 32.20% | 股份 |
| Meros Investment Management, LP | $1125401 | 182992 | 20.41% | 股份 |
| VANGUARD GROUP INC | $1092570 | 1633139 | 19.82% | 股份 |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | $879954 | 143082 | 15.96% | 股份 |
| TWO SIGMA ADVISERS, LP | $587578 | 878556 | 10.66% | 股份 |
| Nuveen Asset Management, LLC | $40837 | 19354 | 0.74% | 股份 |
| Point72 Asia (Singapore) Pte. Ltd. | $6445 | 14697 | 0.12% | 股份 |
| WOLVERINE TRADING, LLC | $5102 | 11600 | 0.09% | 买入期权 |
| Financial Connections Group, Inc. | $0 | 30 | 0.00% | 股份 |
公司内部人士 35 位内幕人士 · 14 位高管 · 18 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| John D Duke | Chief Executive Officer | 2026年3月20日 A | 180000 | 1 | 0 | $25050 |
| Jeffrey Duchemin | Chief Executive Officer | 2019年7月7日 D | 464528 | 0 | 0 | $0 |
| Mark T Frost | Chief Financial Officer | 2026年3月20日 A | 47500 | 1 | 0 | $25000 |
| Jennifer Cote | Chief Financial Officer | 2025年3月19日 F | 159019 | 0 | 0 | $0 |
| Michael A. Rossi | Chief Financial Officer | 2022年12月29日 F | 260540 | 0 | 0 | $0 |
| Kamalam Unninayar | Chief Financial Officer | 2019年3月7日 A | 73858 | 0 | 0 | $0 |
| Bryce Anthony Chicoyne | Chief Financial Officer | 2007年5月1日 A | — | 0 | 0 | $0 |
| Mark A Norige | President, Harvard Apparatus | 2007年5月1日 A | — | 0 | 0 | $0 |
| David L Strack | President of Subsidiary | 2005年5月25日 A | — | 0 | 0 | $0 |
| Kenneth Fletcher Olson | Chief Operating Officer | 2021年12月29日 F | 155595 | 0 | 0 | $0 |
| Yash Singh | Executive Vice President | 2019年10月31日 A | 39286 | 0 | 0 | $0 |
| Yong Sun | VP - Commercial Operations | 2019年1月1日 F | 242805 | 0 | 0 | $0 |
| Yoav Sibony | VP - Global Sales | 2015年8月3日 A | 21582 | 0 | 0 | $0 |
| Paul Bailey | VP, Finance & Admin. | 2005年5月25日 A | — | 0 | 0 | $0 |
| Seth Benjamin Benson | 董事 | 2026年6月9日 A | 27556 | 0 | 0 | $0 |
| Katherine A. Eade | 董事 | 2026年6月9日 A | 58669 | 0 | 0 | $0 |
| Robert E. Gagnon | 董事 | 2026年6月9日 A | 27556 | 0 | 0 | $0 |
| William Snider | 董事 | 2026年6月9日 A | 48556 | 2 | 0 | $103604 |
| Stephen J Denelsky | 董事 | 2026年6月9日 A | 37556 | 1 | 0 | $48700 |
| James W Green | 董事 | 2025年8月15日 D | 2452566 | 0 | 0 | $0 |
| Thomas W Loewald | 董事 | 2024年5月21日 A | 295311 | 0 | 0 | $0 |
| Bertrand Loy | 董事 | 2024年5月21日 A | 56575 | 0 | 0 | $0 |
| Alan I Edrick | 董事 | 2024年5月21日 A | 273911 | 0 | 0 | $0 |
| John F Kennedy | 董事 | 2021年3月23日 G | 323344 | 0 | 0 | $0 |
| Susan M. Steele | 董事 | 2021年1月4日 A | 49400 | 0 | 0 | $0 |
| George Uveges | 董事 | 2018年3月12日 M | 142685 | 0 | 0 | $0 |
| Earl R Lewis | 董事 | 2018年1月2日 A | 477050 | 0 | 0 | $0 |
| David Green | 董事 | 2017年2月7日 S | 925571 | 0 | 0 | $0 |
| Neal J Harte | 董事 | 2016年5月25日 M | 106399 | 0 | 0 | $0 |
| Robert A Dishman | 董事 | 2015年4月28日 A | 51055 | 0 | 0 | $0 |
| Chane Graziano | 10% 所有者 | 2013年11月7日 G | 3005150 | 0 | 0 | $0 |
| HARVARD BIOSCIENCE INC | 10% 所有者 | 2013年11月1日 J | 0 | 0 | 0 | $0 |
| HSO LIMITED PARTNERSHIP | 10% 所有者 | 2008年5月16日 S | 2757257 | 0 | 0 | $0 |
| Thomas Mcnaughton | — | 2013年11月1日 J | 171613 | 0 | 0 | $0 |
| Susan M Luscinski | — | 2013年11月1日 J | 469720 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
激进投资者及 5%+ 股东 5 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| BroadOak Income Fund, L.P., BroadOak Fund VI, L.P., BroadOak Capital Partners, LLC, William Snider | 2026年3月23日 | 15.97% | 初始申报 | — | SEC |
| ENGINE CAPITAL, L.P., ENGINE JET CAPITAL, L.P., ENGINE CAPITAL MANAGEMENT, LP, ENGINE CAPITAL MANAGEMENT GP, LLC, ENGINE INVESTMENTS, LLC, ARNAUD AJDLER ×5 申报 | 2020年6月22日 | — | 初始申报 | — | SEC |
| HSO Limited Partnership Skystone Advisors LLC Kerry Nelson ×2 申报 | 2008年5月20日 | — | 初始申报 | — | SEC |
| 2007年12月14日 | — | 初始申报 | — | SEC | |
| 未披露的报告人 | 2002年7月29日 | — | 初始申报 | 并购/出售 | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF持仓 由 2 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。